Psychiatry · Las Vegas, NV
NPI
1922057116
Since 2006
Specialty
Psychiatry
Code 2084P0800X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
888 W Bonneville Ave
Las Vegas, NV, 89106
Phone (702) 483-6048
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
13,609 services
Medicare patients, 2024
952
Average age 75
Drug cost, 2024
$324K
1,112 prescriptions
Company payments, 2025
$10K
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dylan Wint was code A9575 (injection, gadoterate meglumine, 0.1 ml), 10,852 times for 73 patients. In total Dylan Wint billed 13,609 services in 58 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-05-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| A9575 Injection, gadoterate meglumine, 0.1 ml | Office | 10,852 | 73 | $0.09 | $1,005 |
| 70551 MRI/MRA - Head and Neck | Office | 492 | 416 | $96.27 | $47K |
| 76377 Standard X-ray | Office | 346 | 313 | $33.04 | $11K |
| A9586 Florbetapir f18, diagnostic, per study dose, up to 10 millicuries | Office | 207 | 205 | $2,553.05 | $528K |
| 78814 PET- Oncology | Office | 200 | 195 | $1,187.27 | $237K |
| 99215 Office E&M - Established | Office | 184 | 145 | $123.89 | $23K |
| 99205 Office E&M - New | Office | 136 | 136 | $155.58 | $21K |
| A9584 Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | Office | 104 | 103 | $2,201.52 | $229K |
| 78803 Nuclear | Office | 99 | 99 | $199.86 | $20K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 94 | 83 | $12.78 | $1,201 |
| 0866T MRI/MRA - Head and Neck | Office | 89 | 87 | $103.74 | $9,233 |
| A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 89 | 89 | $195.49 | $17K |
| 78608 PET- Oncology | Office | 80 | 76 | $1,181.26 | $95K |
| 97530 PT Treatment | Office | 75 | 26 | $22.85 | $1,713 |
| 70553 MRI/MRA - Head and Neck | Office | 58 | 56 | $149.66 | $8,680 |
By year: 2022 $274K for 11,806 services; 2023 $432K for 15,764 services; 2024 $1.3M for 13,609 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 15 | 15 | $8.65 | $130 |
Medicare prescription drug claims, 2024
In 2024, the drug Dylan Wint prescribed most often to Medicare patients was Donepezil Hcl, with 284 prescriptions and refills. In total Dylan Wint wrote 1,112 Medicare prescriptions that cost $324K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Donepezil Hcl Generic | 284 | 657 | 108 | $2,689 |
| Memantine Hcl Generic | 77 | 194 | 32 | $2,425 |
| Escitalopram Oxalate Generic | 74 | 185 | 36 | $1,069 |
| Rivastigmine Generic | 44 | 72 | 14 | $8,790 |
| Galantamine Er Galantamine Hbr | 42 | 94 | 14 | $5,920 |
| Aripiprazole Generic | 40 | 68 | 11 | $1,072 |
| Duloxetine Hcl Generic | 40 | 74 | Under 11 | $771 |
| Venlafaxine Hcl Er Venlafaxine Hcl | 37 | 71 | Under 11 | $1,072 |
| Quetiapine Fumarate Er Quetiapine Fumarate | 35 | 53 | Under 11 | $1,351 |
| Trazodone Hcl Generic | 32 | 82 | Under 11 | $391 |
| Nuplazid Pimavanserin Tartrate | 30 | 34 | Under 11 | $239K |
| Clonazepam Generic | 27 | 31 | Under 11 | $678 |
| Memantine Hcl Er Memantine Hcl | 27 | 65 | Under 11 | $4,806 |
| Bupropion Xl Bupropion Hcl | 26 | 43 | Under 11 | $610 |
| Sertraline Hcl Generic | 25 | 45 | Under 11 | $145 |
Brand drugs: 87 claims; generic drugs: 1,025 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dylan Wint $10K ($10K in general payments such as food, travel and fees) from 6 companies. The largest payer was Biogen, Inc. with $7,005.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.